Clinical trial NCT03442088
Conditions: Plaque Psoriasis
Sponsor: University Hospitals Cleveland Medical Center
Start date: 2018-06-01; Completion date: 2021-09-30
Enrollment: 28 participants; Allocation: NA; Intervention model: SINGLE_GROUP

Brief summary:
This is an open label pilot study of the impact of treatment with standard dosing of Otezla for 16 weeks on AM-endotype psoriasis patients, identified by elevated (\>150% of normal): 1.) Intermediate (CD14++CD16+) monocytes, or 2.) circulating monocyte doublets, or 3.) circulating monocyte-platelet aggregates (MPA).

Approximately 25 psoriasis patients with the AM-endotype will be followed during treatment over 16 weeks with 4 monthly individual blood draws will be enrolled. All treated psoriasis subjects will receive apremilast through Week 16.

Detailed description:

Arms: arm 1: Psoriasis patients with the AM-endotype will be followed during treatment over 16 weeks with 5 monthly individual blood draws will be enrolled.
Interventions: intervention 1: Apremilast
Intervention descriptions: intervention 1: Apremilast will be given as approved by the FDA for the treatment of moderate to severe plaque psoriasis. An initial dosage titration from Day 1 (10mg) to Day 5 (30mg). Following the titration, the recommended maintenance dosage of 30 mg twice daily taken orally starting on Day 6 will be dispensed, as per labeled indication.

Protocol documents:
Prot_SAP_000.pdf: 
1
An Investigator Initiated Study of Monocyte Biomarkers 
in Moderate to Severe Plaque Psoriasis Subjects Treated 
with Apremilast 
INVESTIGATIONAL PRODUCT (IP): Apremilast 
PROTOCOL NUMBER: UH IRB# 07-17-33
Amgen study 20207105
VERSION: 8.0 Date:  27May2021
SPONSOR NAME / ADDRESS: 
Dr. Neil Korman
University Hospitals Cleveland Medical Center (UHCMC)
Department of Dermatology
11000 Euclid Ave.
Cleveland OH, 44106


2
MEDICAL MONITOR / EMERGENCY CONTACT INFORMATION
Contact Information:
Name:
Neil J. Korman, MD, PhD
Title:
Director, Clinical Trials Unit
Address:
University Hospitals Cleveland Medical Center
Department of Dermatology
11100 Euclid Avenue
Cleveland, OH 44106
Phone:
216-844-3111
E-mail:
Neil.Korman@uhhospitals.org


3
PROTOCOL SUMMARY
Study Title
Otezla Reversal of Psoriasis Aberrant Monocyte CVD Event-Risk Biomarkers
Indication
Psoriasis is a chronic disease that requires long-term treatment, ideally with effective agents that 
offer convenient dosing and a low incidence of adverse events. Currently available systemic 
therapies are limited by risks of hepatic, renal and neurological toxicities, teratogenicity, as well 
as an increased risk of infections and malignancies.  Most biologic therapies designed to treat 
psoriasis are administered parenterally. Given the limitations of current systemic psoriasis 
treatments, there is an unmet medical need for an effective oral agent that is well tolerated and less 
immunosuppressive than the current oral agents and parenteral biologics.
Apremilast (Otezla) is a specific phosphodiesterase type 4 (PDE4) inhibitor used in the 
treatment of inflammatory conditions.  PDE4 is one of the major phosphodiesterases 
expressed in leukocytes.  Inhibitors of PDE4 cause accumulation of intracellular cyclic 
adenosine monophosphate (cAMP), resulting in inhibition of pro- inflammatory cytokine 
transcription and other cellular responses, such as neutrophil degranulation and chemotaxis.
Apremilast has demonstrated broad anti-inflammatory and immunomodulatory activity, as well 
as efficacy in psoriasis and psoriatic arthritis.  Based on preclinical and clinical data to date, 
apremilast has a more favorable safety profile than the currently available systemic psoriasis 
treatments, while delivering efficacy with convenient oral dosing.
Objectives
Primary Objective

Evaluate aberrant inflammatory profiles of activated blood monocytes known as the 
aberrant-monocyte endotype (i.e. AM-endotype)

Assess the median reduction of abnormal monocyte biomarker values in AM-
endotype patients treated with oral apremilast (Otezla) under recommended dosing:

Day 1: 10 mg in morning

Day 2: 10 mg in morning and 10 mg in evening 

Day 3: 10 mg in morning and 20 mg in evening 

Day 4: 20 mg in morning and 20 mg in evening

Day 5: 20 mg in morning and 30 mg in evening  

Day 6 - Day 112: 30 mg twice daily
Secondary Objectives

Evaluate the median change in serum myeloperoxidase, resistin, IL-17, and Tissue 
Factor in the AM-endotype.

Evaluate the median change in flow cytometric quantitation of additional monocyte 
and neutrophil markers, including CD18/CD11b and NETotic neutrophils.  

Evaluate change in monocyte transcriptome biomarkers by WGS.


4
Other Objective(s)

Evaluate Health Related Quality of Life (HRQoL) (Dermatology Life Quality 
Index (DLQI) and (Work Productivity and Activity Impairment Questionnaire: 
Psoriasis (WPAI: PSO)) and changes in symptom severity of patients receiving 
apremilast 30 mg BID.

Explore potential change in Framingham Risk profile of treated patients.
Study Design
This is an open label pilot study of the impact of treatment with standard dosing of APM for 16 
weeks on AM-endotype psoriasis patients, identified by elevated (>150% of normal):  
1.
Intermediate (CD14++CD16+) monocytes (i.e. monocytes in circulation), OR
2.
Circulating monocyte doublets (i.e adherent monocyte-monocyte pairs), OR
3.
Circulating monocyte-platelet aggregates (i.e. monocytes adherent to platelets; MPA).   
Approximately 25 psoriasis patients with the AM-endotype will be followed during treatment over 
16 weeks with 5 monthly individual blood draws will be enrolled. 10 untreated healthy controls will 
also be enrolled and will provide two blood draws (baseline and 16 weeks).  These are needed to 
maintain quality control of the normal levels of the biomarkers being tested. All treated psoriasis 
subjects will receive apremilast through Week 16
 
Study Population
Adult subjects 18-65 years of age with moderate-to-severe plaque psoriasis.
Healthy controls
Healthy participants will be recruited from a pool of generally healthy research volunteers. Healthy 
volunteers will be selected to match age, sex, and race of psoriasis subjects as closely as possible.
Length of Study
Analysis of myeloid 
biomarkers:
Intermediate Monocytes
Circulating Monocyte 
Doublets
Monocyte/Platelet 
Aggregates
Correlation of myeloid 
biomarker changes with:
• Clinical values
• Framingham 10 year risk %
• PASI 75/90
Study Design
Screening & 
2 week washout
Treatment (Apremilast30mg BID)
Analysis
Visit 1: 
Screening
Visit 3:
4 weeks
Visit 4:
8 weeks
Visit 5:
12 weeks
Final Visit:
16 weeks
n=25 moderate-severe psoriasis patients
n=10 Healthy Controls
Visit 2: 
Baseline
Blood draws at each visit for PBMC prep and monocyte evaluations


5
The study is designed as a 16 week study and consists of 6 distinct visits as described above. 
Screening will consist of a 1a and optional 1b visit.  Visit 1b is optional.  It exists so that the subject 
can pick up the Empatica E4 wrist device that cannot be given until their monocyte profile is known. 
Visits 3 and 5 will also be split into part a and b. Visit b will is optional.  If the subject choses to 
participate, visit b is when the subject returns the wrist device.
Study Treatments
Apremilast will be dispensed in dose titration cards at Visit 2.  At Visit 3, apremilast tablets will be 
supplied in high density polyethylene (HDPE) bottles containing approximately 60 tablets each.
Overview of Efficacy Assessments
Primary Clinical Assessment 
The primary clinical assessment will be Psoriasis Area and Severity Index (PASI) scores.
Additional Clinical Assessments  

Static Physician’s Global Assessment (sPGA)

Body Surface Area (BSA)

Subject’s Assessment of Pruritus VAS

Subject’s Assessment of Skin Discomfort/Pain VAS

Subject Global Assessment of Psoriasis Disease Activity VAS

Subject’s Assessment of Joint Pain VAS

Subject Global Assessment of Psoriatic Arthritis Disease Activity VAS

Health Related Quality of Life (HRQoL) questionnaires:

Dermatology Life Quality Index (DLQI)

Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI: 
PSO)
Overview of Safety Assessments  
Safety Assessments

Adverse events (AE)

Physical examinations

Vital signs

Clinical laboratory tests

Evaluation of psoriasis flare or rebound.


6
1.
INTRODUCTION
1.1.
Apremilast
Apremilast (Otezla) is an oral agent that modulates multiple inflammatory pathways through 
targeted phosphodiesterase type 4 (PDE4) enzyme inhibition.  It is used for the treatment of 
inflammatory autoimmune disorders, such as psoriatic arthritis and psoriasis that involve elevated 
cytokine levels.
PDE4 is one of the major phosphodiesterases expressed in leukocytes. Inhibitors of PDE4 cause 
accumulation of intracellular cyclic adenosine monophosphate (cAMP), resulting in inhibition of 
pro-inflammatory cytokine transcription and other cellular responses such as neutrophil 
degranulation and chemotaxis.
1.2.
Psoriasis
Disease significance: The prevalence of skin disease exceeds those of obesity, hypertension or 
cancer. One in three Americans suffers with a skin disease, and ~2-3% of these individuals have 
psoriasis. Costs of treating these patients are believed to exceed $1B, including over $350M in 
prescriptions alone [1-5].  Chronic inflammation in psoriasis is often not limited to the skin, as 
evidenced by a high frequency of other significant co-morbidities including psoriatic arthritis,  
inflammatory bowel disease, lymphoma, obesity and metabolic syndrome [6-8], and recent evidence 
indicates that psoriasis patients have increased risk of developing and dying of cardiovascular 
diseases (CVD) [9]. Psoriasis patients also experience increased emotional burden via increased 
depression, mood disorders and suicidal ideation [10], an impact which may be purely from reactions 
to disfigurement, but which may also be a result of sensors in the brain of distant (skin) inflammation. 
Intervention at several points during the inflammatory disease cycle of psoriasis has revolutionized 
the understanding of psoriasis, and can produce clinical resolution in many, but not all patients.  
Improving understanding of psoriasis benefits not only the quality of life for patients with psoriasis, 
but also other inflammatory diseases of skin and other organs, as drugs initially developed for 
psoriasis have been extended to other indications.  In particular, work that can be leveraged to other 
conditions remains to be done in unraveling the complex systemic interactions involving neurologic, 
immunologic, genetic, cellular and cutaneous biology responsible for the inflammatory responses in 
other organ systems when initiated by the skin of active psoriasis, or cutaneous GVHD, or dermatitis 
[11].  Toward that end, improved understanding of psoriatic inflammation  progressively moved 
treatment upstream from broad immunologic suppression (i.e., cyclosporine or steroids) to somewhat 
more targeted but still fairly broad approaches (LFA-3-FcIgG, anti LFA-1, TNF inhibitors), to 
upstream Monocyte/Dendritic cell cytokine-initiated pathways (i.e., IL-12 p40, IL-23, PDE4) that 
drive a highly specific T cell lineage (Th17) mediating skin psoriasis.  
  
CELLULAR COMPONENTS 
Monocytes:  Monocytes (Mon’s) and their derived subpopulations are highly plastic and sensitive 
sentinels of inflammation.  They play a critical role in psoriasis, are extremely strong candidates for 
mediating aspects of co-morbidities associated with psoriasis, and appear to be useful as biomarkers 
of Framingham Risk associated with psoriasis.  However, there is extremely limited understanding 
of how Mon’s respond to the chronic inflammatory stimuli they encounter either as developing 
precursors in the bone marrow (BM) or upon egress into circulation and interaction with the activated 
endothelium of a psoriatic lesion.  Distinct circulating Mon populations arise from a common 
granulocytic-macrophage myeloid precursor in the BM, and have been genotyped; classical 


7
monocytes (Mon-1, CD14++ CD16neg), intermediate monocytes (Mon-2, CD14++ CD16+) and non-
classical monocytes (Mon-3, CD14- CD16++) [12-18].  It is believed that Mons do not proliferate in 
circulation and reconstitution of the Mon pool is accomplished through maturation of a common 
BM-derived common myeloid progenitor.  Mon-1s comprise the majority of circulating Mons that 
interact with endothelial cells (EC) and plasma proteins for approximately 1-3 days [19, 20], and 
then traverse the endothelium and enter tissue.  Initial Mon-1 binding to EC are postulated to result 
in two potential outcomes; 1) cells that adhere and extravasate directly into surrounding tissue are 
likely to differentiate into macrophages and/or dendritic cell subsets, and 2) Mon-1 cells that do not 
extravasate, but transiently interact with endothelia and release, triggering transition to Mon-2 
intermediate cells.
Among the Mon subsets [12-18] Mon-2s have been reported to produce elevated levels of TNF 
upon challenge, and exhibit reduced levels of IL-10 production--they have therefore been identified 
as pro-inflammatory. Mon-2 are also the main producers of reactive oxygen species (ROS) [16] and 
secrete pro-atherogenic micro-particles (MP’s) (also elevated in psoriasis) [21, 22].  Indeed, 
myeloperoxidase (MPO) is elevated in psoriasis serum and appears derived from tissue 
Mon’s/macrophages [23].   Activated Mon-2 cells also exhibit high levels of the angiogenic factors 
ENG and Tie2 (TEK), and appear upregulated for trans-endothelial migration to tissue via CCR2, 
CX3CR1, CXCR4,and ICAM-1 receptors [16].  They demonstrate enhanced antigen processing, and 
can be precursors to tissue macrophages, dendritic cells and other professional antigen presenting 
cells that initiate and direct T cell mediated response to antigenic challenge.   Mon-2’s also express 
the highest level of the toll-like receptor 4 (TLR-4) [24, 25] for which a number of endogenous 
ligands are overexpressed in psoriasis (i.e., EDA fibronectin, S100 A8/9/12) [26, 27] . 
Circulating Mon-2 cells are biomarkers of inflammation in numerous diseases [28-35], and are 
validated predictive biomarkers of cardiovascular disease (CVD) events [36], including myocardial 
infarction and death [24, 37, 38]    Indeed, psoriasis patients have elevated levels of circulating CD16+ 
cells, which contain the Mon-2 population [29, 39], and we and others have shown that Mon-2s are 
elevated in a subset of psoriasis patients [29, 39, 40].    We also discovered, in addition to elevations 
of Mon2’s that Mons in psoriasis are more highly aggregated and can carry adherent platelets. These 
self-aggregated Mons exhibit a differential transcriptional profile from other singlet Mon populations 
[40]. 
Skin inflammation, most explored in psoriasis, but also apparent in GVHD, dermatitis, and skin 
injury, appears to be detected by distant cells of the myeloid lineage, with clinical functional 
consequences.  Monocytic cells are designed to be sensors of inflammatory perturbations, and have 
the capability to differentiate down multiple pathways, as appropriate to the signals.  Their timing is 
intermediate between neutrophils and lymphocytes (3-14 days in circulation), and as such are very 
attractive candidates for giving us a practical “smoking gun” regarding recent signals that have been 
received, as well as giving us a handle on what type of effector functionality has been triggered.  
1.3.
Key Findings from Non-clinical Studies
1.3.1.
In Vitro Activity
In lipopolysaccharide (LPS)-challenged peripheral blood mononuclear cells (PBMCs), 
apremilast inhibited, in order of increasing potency, IP-10, IFN-γ, MIG, TNF-α, IL-12p70, 
MIP-1α, MCP-1, and GM-CSF production.  Reduction of TNF-α, IFN- γ, IL-12, and IL-23


8
expression occurred at the mRNA level.  It also inhibited IFN-γ and IL-2 production by PBMC 
stimulated with staphylococcal enterotoxin B.  In purified human NK cells, apremilast inhibited 
production of TNF-α and GM-CSF.  Production of IL-8 and leukotriene B4 by PMN and TNF-α 
production by human epidermal keratinocytes were also blocked by apremilast in vitro. Apremilast 
was tested in a model of psoriasis utilizing normal human skin xenotransplanted onto beige-severe 
combined immunodeficient (SCID) mice and triggered with human psoriatic NK cells.  Orally 
administered apremilast (5 mg/kg/day) significantly reduced epidermal thickness and proliferation 
and decreased the general histopathologic appearance of psoriasiform features. Staining for TNF-
α, HLA-DR, and ICAM-1 in lesional skin was also qualitatively reduced by apremilast treatment 
[41].  
1.3.2.
In Vivo Anti-arthritic and Anti-inflammatory Activity in Animals
In a mouse xenograft model of human psoriasis, apremilast reduced the appearance of 
psoriasiform lesions, reduced epidermal thickness and keratinocyte proliferation, and inhibited 
HLA-DR and ICAM-1 expression in the engrafted human skin [41].  Apremilast reduced TNF-
α production in mice in response to LPS and reduced paw edema in a type II collagen-induced 
model of arthritis in mice.
1.4.
Rationale for Dose Chosen
Apremilast
Apremilast will be given as approved by the FDA for the treatment of moderate-to-severe plaque 
psoriasis.  An initial dosage titration from Day 1 to Day 5 will be performed as shown below:
Dosing titration schedule for week 1
Day 1
Day 2
Day 3
Day 4
Day 5+
am
pm
am
pm
am
pm
am
pm
am
pm
10mg
x
10mg
20mg
20mg
20mg
20mg
30mg
30mg
30mg
Following the titration, the recommended maintenance dosage of 30 mg twice daily taken orally 
will be continued throughout the study.


9
1.5.
Relevant Reference and Background
Psoriasis is a chronic disease that requires long-term treatment, ideally with effective agents that 
offer convenient dosing and a low incidence of adverse events.  Currently available systemic 
therapies are limited by risks of hepatic, renal and neurological toxicities, teratogenicity, as well 
as an increased risk of infections and malignancies. Given the limitations of current systemic 
psoriasis treatments, there is an unmet medical need for an effective oral agent that is well tolerated 
and less immunosuppressive than the current oral agents and parenteral biologics.  In completed 
studies in psoriasis and psoriatic arthritis, apremilast has demonstrated broad anti-inflammatory 
and immunomodulatory activity. Efficacy in psoriasis and psoriatic arthritis has also been 
demonstrated.  Based on preclinical and clinical data to date, apremilast has a favorable safety 
profile compared to the currently available systemic psoriasis treatments, while delivering efficacy 
with convenient oral dosing.
Methotrexate (MTX), retinoids, cyclosporine (CsA), and psoralen plus long-wave ultraviolet 
radiation (PUVA) form the group of most commonly used conventional systemic therapies for 
moderate to severe plaque-type psoriasis.  These treatments have varied levels of effectiveness 
and are often associated with adverse reactions and dose limiting toxicities, such as 
myelosuppression (MTX), hepatotoxicity (MTX), nephrotoxicity (CsA), teratogenicity (MTX, 
retinoids), and increased risk of malignancy and serious infections (CsA, PUVA).
Advances in the understanding of the biochemical mechanisms associated with psoriasis have led 
to the development of more specific therapies for this disease [42].  During the past 10 to 15 
years, a number of biologic agents that act on specific steps in the immunologic cascade that 
controls psoriasis have been identified.  Examples include infliximab, adalimumab and etanercept 
(inhibitors of TNF), and ustekinumab (inhibitor of IL-12 and IL-23). Etanercept, adalimumab 
and infliximab work by inactivation of TNF ([43]; [44]). Ustekinumab is a monoclonal antibody 
that acts by binding to the p40 subunit of human IL-12 and IL-23 [45], and blocking their 
interaction with Th1 and Th17 cells, respectively. While the biological agents have demonstrated 
efficacy in moderate-to-severe psoriasis, they may be associated with several safety concerns 
including injection site reactions, opportunistic infections, reactivation of tuberculosis, congestive 
heart failure, and new onset or exacerbation of demyelinating disease ([46]; [47]).


10
2.
Study Objectives
Primary Objective

Evaluate aberrant inflammatory profiles of activated blood monocytes known as the 
aberrant-monocyte endotype (i.e. AM-endotype)

Assess the median reduction of abnormal monocyte biomarker values in AM-
endotype patients treated with oral apremilast (Otezla) under standard dosing for 16 
weeks in subjects with moderate to severe plaque psoriasis.  
Comparisons will be from baseline to 16 weeks within each patient using baseline as the 
starting point and following 16 weeks as the comparators.  This comparison is also true 
for the secondary objectives. 
Secondary Objectives

Evaluate the median change in serum myeloperoxidase, resistin, IL-17, and Tissue 
Factor in the AM-endotype.  

Evaluate the median change in flow cytometric quantitation of additional monocyte 
and neutrophil markers, including CD18/CD11b and NETotic neutrophils.

Evaluate change in monocyte transcriptome biomarkers by WGS.
Other Objective(s)

Evaluate Health Related Quality of Life (HRQoL) (Dermatology Life Quality 
Index (DLQI) and (Work Productivity and Activity Impairment Questionnaire: 
Psoriasis (WPAI: PSO)) and changes in symptom severity of patients treated with 
apremilast 30 mg BID.

Explore potential change in Framingham Risk profile of treated patients


11
3.            OVERALL STUDY DESIGN
This is an open label pilot study of the impact of treatment with standard dosing of apremilast for 16 
weeks on AM-endotype psoriasis patients, identified by elevated (>150% of normal):
1.) Intermediate (CD14++CD16+) monocytes, OR 
2.) Circulating monocyte doublets, OR
3.) Circulating monocyte-platelet aggregates (MPA).   
Study Population
Adult subjects 18-65 years of age with moderate-to-severe chronic plaque psoriasis.
Length of Study
The study is designed as a 16 week study starting from the time the patient is enrolled at baseline. 
The preceding screening period is 35 days. 
3.1
Data and Safety Monitoring Plan
The investigators will closely monitor the subjects in this study and safety monitoring will be 
performed and adverse event data will be collected by the primary investigator and sub-
investigator at University Hospitals Cleveland Medical Center (UHCMC) at each study visit.  If 
any serious adverse or unexpected events were to occur, subjects will be asked to call Dr. Neil 
Korman or the primary dermatologist providing care to the subject.  The subject will be asked 
to come in as soon as possible for evaluation by a physician co-investigator.  After appropriate 
measures are carried out, the adverse event and how it was handled will be documented and 
reported to the IRB according to UHCMC IRB policy.  The PI and the IRB will then decide if 
changes to the protocol or consent form are needed.
3.2.
Study Design Rationale
Most of the currently available oral systemic therapies for psoriasis are associated with significant 
cumulative toxicities which have often required physicians to use different treatment regimens 
(e.g., rotational, intermittent, sequential) in order to balance drug toxicities with their therapeutic 
effect.  Given the chronic nature of psoriasis, there is a need for medication that can be dosed 
chronically with less risk.  It is, therefore, important for new medications to demonstrate both 
efficacy and safety with continuous use.
This study will evaluate aberrant inflammatory profiles of activated blood monocytes (aberrant-
monocyte endotype patients (AM-endotype) and assess the median reduction of abnormal 
monocyte biomarker values in AM-endotype patients treated with oral apremilast (Otezla) under 
standard dosing protocol for 16 weeks in subjects with moderate to severe plaque psoriasis.
3.3.
Study Duration
Subjects who complete the entire study will spend a total of approximately 16 
weeks in the study:

Up to 35 days in the Screening Phase

Weeks 0 to 16 (i.e., 16 weeks) in the Apremilast treatment phase.


12
4.  TABLE OF EVENTS
Screening 
Part 1
Screening 
Part 2
Baseline 
2A
Baseline 
2B
Apremilast Treatment
Visit
1a
1b
2A
2B
3
3b
4
5
5b
6
Week
Up to 35 days
0
1
4
5
8
12
13
16
Informed Consent
X
-
-
Inclusion/Exclusion
Criteria
X
Medical and Disease
History
X
X
Prior/Concurrent
Medications/ 
Therapies
X
X
X
X
X
X
X
Peripheral blood draw
X
X
X
X
X
X
Safety Assessments
Pregnancy Test and 
Contraception 
Education for 
Females of Child- 
bearing Potential
(FCBP)
X
X
Vital Signs
X
X
X
X
X
X
Height
X
-
Weight / Waist
Circumference/BMI
X
       X
X
X
X
X
Complete Physical
Examination
X
-
Limited Physical
Examination
-
X
X
X
X
X
Complete blood 
count with 
differential, , 
comprehensive 
metabolic panel, 
phosphorous, high 
sensitivity C-reactive 
protein 
X
X
X
X
X
Total cholesterol, 
triglycerides, high 
density lipoprotein 
cholesterol, low 
density lipoprotein 
cholesterol, fasting 
glucose level, insulin, 
hemoglobin A1C, 
glucose tolerance 
test (GTT; optional), 
Plasma 
catecholamines 
fractioned 
(epinephrine, 
X
X


13
norepinephrine, 
dopamine)
Monocyte 
Assessment (Doublet 
%, Classical, 
Intermediate, Non-
Classical circulating 
%, Total PBMCs , 
Viability, Monocyte 
Number/ml blood 
and , Monocyte gene 
expression)
X
X
X
X
X
X
Dispense monitoring 
device for 
electrodermal 
activity (Empatica E4 
wristband) ± laptop 
(Optional)
X
X
X
Return Empatica E4 
wristband ± laptop 
(Optional)
X
X
X
Psoriasis Flare or
Rebound Assessment
-
        
X
      
X
X
X
X
Adverse Events
X
X
X
X
X
X
X
Clinical Efficacy Assessments
PASI, BSA, sPGA
X
X
X
X
X
X
Pruritus VAS
-
X
X
X
X
X
Skin 
Discomfort/ 
Pain VAS
-
X
X
X
X
X
Subject 
Assessment of 
Joint pain VAS; 
Subject Global 
PsA VAS; HAQ-DIn
-
X
X
X
X
X
Subject Global 
Assessment of 
Psoriasis 
Disease 
Activity VAS
-
X
X
X
X
X
Health-related Quality of Life Assessments
DLQI, 
-
X
X
X
X
X
WPAI, 
-
X
X
X
X
X
Stress Response Assessment
Numerical N-Back
X
X
X
Investigational Product  Dosing
Dispense IP 
titration cards
-
x
Dispense IP bottles
-
-
X
X
X
Return IP tablets, 
Count for 
Compliance
-
_
X
X
X
X
Dispense 
Medication Log
x
X
X
X
Return Medication 
Log
X
X
X
X


14
*Except for screening, all visits have a +/- 3 day window in which they can be completed.
**Diabetic patients will not undergo the glucose tolerance test for patient safety.
5. PROCEDURES
The following procedures will be conducted as outlined in the Table of Events.
Informed Consent
An Informed Consent Document will be signed by the subject before any study-related assessments 
are performed.  
Contraception Education
At Screening and at Baseline, and at any time during the study when a female subject of 
childbearing potential’s contraceptive measures or ability to become pregnant changes, the 
Investigator will educate the subject regarding contraception options and correct and consistent use 
of effective contraceptive methods in order to successfully prevent pregnancy.
Inclusion/Exclusion Criteria
Subjects must meet all inclusion criteria and must not have any of the conditions specified in the 
exclusion criteria to qualify for participation in the study. The subject’s source documents must 
support his/her qualifications for the study (e.g., if a female subject does not require pregnancy 
testing and birth control because of a hysterectomy, the date of the hysterectomy must be included 
in the medical history).
Medical and Disease History
Relevant medical history, as defined in the electronic Case Report Form (eCRF) Completion 
Guidelines and the Study Manual, should be recorded, including smoking and alcohol history, as 
well as previous relevant surgeries.  Disease history includes history of psoriasis and psoriatic 
arthritis.
Prior/Concurrent Medications and Therapies
All medications and therapies being taken/used by the subject at the time of consent or at any time 
during the study will be recorded.  Other key medications and therapies, such as previous treatment 
for tuberculosis (TB) or relevant diseases, will be recorded.  
All medications and therapies for psoriasis, including topicals (used within the last 5 years), 
systemics, and all medications and therapies for psoriatic arthritis, will be recorded. The stop 
dates for all medications and therapies prohibited in the study will be recorded.  Responses to 
prior psoriasis therapies will also be recorded. 
Safety Assessments     
The following assessments will be conducted as outlined in the Table of Events.
  Vital Signs, Height, and Weight
Vital signs, including temperature, pulse, and seated blood pressure, will be taken during the visits 
indicated in Table of events.  Height will be measured and recorded at Screening; weight and 
waist circumference will also be measured and recorded at Screening and then as indicated in 


15
Table of events.  Body mass index (BMI) will be calculated.
  Complete/Limited Physical Examination 
A complete physical examination includes evaluations of skin, nasal cavities, eyes, ears, lymph 
nodes, and respiratory, cardiovascular, gastrointestinal, neurological, and musculoskeletal 
systems.  The complete physical examination is done at Screening and other designated visits.  
A limited physical examination includes evaluations of skin, lymph nodes, and respiratory, 
cardiovascular, and musculoskeletal systems. The limited physical examination is done at 
Baseline and other designated visits as indicated in Table of events.
Clinical Laboratory Evaluations
Clinical laboratory evaluations will be performed as indicated in Table of Events.  Clinical 
laboratory evaluations will include a complete blood count with differential (WBC, nucleated 
RBC, RBC, HGB, HCT, MCV, MCHC, PLT, RDW-CV, WBC differential, WBC absolute cell 
counts), a comprehensive metabolic panel (glucose, sodium, potassium, chloride, bicarbonate, 
anion gap, urea nitrogen, creatinine, GFR, calcium, albumin, alkaline phosphatase, total protein, 
AST, ALT, bilirubin total), phosphorus, and high sensitivity C-reactive protein. Total cholesterol, 
triglycerides, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol 
(LDL-C), fasting glucose level, insulin, hemoglobin A1C, glucose tolerance testing (GTT; 
optional), and plasma catecholamines fractioned (epinephrine, norepinephrine, and dopamine)  
measurements are only required at baseline and week 16 as indicated in the table of events.  Those 
subjects determined to have elevated lipids may elect to participate in a separate assessment 
characterizing their HDL. Monocyte labs will also be collected at each visit (Doublet %, 
Circulating Monocyte % (Classical, Intermediate, Non-Classical), Total PBMCs, Viability, 
Monocyte Number/ml blood). Patients with diabetes mellitus type I and type II will not undergo 
the GTT in order to maintain patient safety.
Monitoring Epidermal Activity (Optional)
The Empatica E4 wearable wrist device will be monitoring for epidermal activity to measure 
sympathetic nervous system arousal and to derive features related to stress, engagement, and 
excitement, as well as activity.  The device is able to record continuous heart rate, activity, 
temperature, and photoethysmography. Patients will be asked to wear the wrist device (Empatica 
E4) for 7 days prior to enrollment, 7 days after a month of apremilast usage, and again for 7 days 
after 3 months of apremilast use. 
In order to use this device, the subject must have access to reliable internet and be able to download 
the compatible data manager interface onto an appropriate electronic device. If the patient does 
not have such a device, a laptop will be provided to the subject to be used solely for the study and 
to be returned with the device.
Psoriasis Flare and Rebound Assessments
Psoriasis flare is an AE (and will be recorded as an AE) and represents an atypical or unusual 


16
worsening of disease during treatment [48].  It is defined as a sudden intensification of psoriasis 
requiring medical intervention or a diagnosis of new generalized erythrodermic, inflammatory, 
or pustular psoriasis.  A more typical, gradual worsening of plaque psoriasis would not be 
recorded as an AE.
Rebound is an AE and is defined as a severe and sudden worsening of disease that occurs after 
treatment has been discontinued.  This exacerbation is characterized by a PASI ≥ 125% of 
baseline or a new generalized pustular, erythrodermic or more inflammatory psoriasis after 
stopping therapy [49].
Pregnancies/lactation and suspected pregnancies (including a positive pregnancy test 
regardless of age or disease state) of a female subject or the female partner of a male subject 
occurring while the subject is on study drug, or within 30 days of the subject’s last dose of study 
drug, are considered immediately reportable events.  Study drug is to be discontinued immediately 
and the subject instructed to return any unused portion of the study drug to the investigator(s).  
The pregnancy, lactation, suspected pregnancy, or positive pregnancy test must be reported to 
AmgenAmgen Safety immediately facsimile using the Pregnancy Report form provided by 
Amgen.
The female should be referred to an obstetrician-gynecologist experienced in reproductive toxicity 
for further evaluation and counseling.
The Investigator(s) will follow the female subject until completion of the pregnancy, and must 
notify Amgen Safety of the outcome of the pregnancy as a follow-up on the follow up Pregnancy 
Reporting form.
If the outcome of the pregnancy meets the criteria for immediate classification as a SAE (i.e., 
spontaneous or therapeutic abortion [any congenital anomaly detected in an aborted fetus is to be 
documented], stillbirth, neonatal death, or congenital anomaly [including that in an aborted 
fetus]), the Investigator(s) should follow the procedures for reporting SAEs (i.e., report the event 
to Amgen Safety by facsimile within 24 hours of the Investigator’s knowledge of the event).
In the case of a live “normal” birth, Amgen Safety should be advised by facsimile within 24 hours 
of the Investigator’s knowledge of the event.
All neonatal deaths that occur within 30 days of birth should be reported, without regard to 
causality, as SAEs.  In addition, any infant death after 30 days that the Investigator(s) suspects is 
related to the in utero exposure to the study drug should also be reported to Amgen Safety by 
facsimile within 24 hours of the Investigators’ knowledge of the event.
If the female is found not to be pregnant, any determination regarding the subject’s continued 
participation in the study will be determined by the Investigator.
Male Subjects
If a female partner of a male subject taking IP becomes pregnant, the male subject taking IP
should notify the Investigator, and the pregnant female partner should be advised to call their
healthcare provider immediately.
Adverse Events
Details of AE reporting may be found in Section 10.


17
Clinical Efficacy Assessments
The following assessments will be conducted as outlined in the Table of Events.
Psoriasis Area Severity Index (PASI)
PASI will be determined for all subjects throughout the study.  The PASI calculation is described 
in Appendix A.
The PASI is a measure of psoriatic disease severity taking into account qualitative lesion 
characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement 
on defined anatomical regions.  The PASI is a validated instrument that has become standard in 
clinical trials for psoriasis.
Psoriasis Area Severity Index scores range from 0 to 72, with higher scores reflecting greater 
disease severity [50].  Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 
(very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs.  
Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no 
involvement) to 6 (90% to 100% involvement).  The total qualitative score (sum of erythema, 
thickness, and scaling scores) is multiplied by the degree of involvement for each anatomic 
region and then multiplied by a constant. These values for each anatomic region are summed to 
yield the PASI score.
   Body Surface Area (BSA)
BSA is a measurement of involved skin.  The overall BSA affected by psoriasis is estimated 
based on the palm area of the subject’s hand (entire palmar surface or “handprint”), which 
equates to approximately 1% of total body surface area.
Physician Global Assessments (PGAs)

Static Physician’s Global Assessment (sPGA)
The sPGA is the assessment by the Investigator of the overall disease severity at the time of 
evaluation.  The sPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an 
assessment of the severity of the three primary signs of the disease: erythema, scaling and 
plaque elevation. When making the assessment of overall severity, the Investigator should 
factor in areas that have already been cleared (i.e. have scores of 0) and not just evaluate 
remaining lesions for severity, i.e., the severity of each sign is averaged across all areas of 
involvement, including cleared lesions.  Areas of cleared lesions may be directly assessed if 
outlines of the original lesions can be directly visualized (e.g., residual hyperpigmentation) or, 
if not, by factoring in the minimum BSA for inclusion in the study (i.e., at least 10%).  In other 
words, if there are small lesions of mild severity covering 1% BSA, but there are cleared lesions 
covering 9+% BSA, over 90% of the severity is clear; this should be integrated into the final 
assessment.  In the event of different severities across signs of psoriasis, the sign that is the 
predominant feature of psoriasis should be used to help determine the sPGA score.  See 
Appendix B for grading criteria.

Health Assessment Questionnaire Disability Index (HAQ-DI)
The HAQ-DI [51]is a 20-question, self-administered instrument that measures the subject’s 
functional ability on a 4-level difficulty scale (0-3, with 0 representing normal or no difficulty; 
and 3 representing inability to perform).  Eight categories of functioning are included:  
dressing, rising, eating, walking, hygiene, reach, grip, and usual activities [52]. This scale is 
sensitive to change and is a good predictor of future disability [53].  See Appendix C.


18
Visual Analog Scale (VAS) Assessments
The following assessments will be conducted as outlined in the Table of Events.

Pruritus Visual Analog Scale (VAS) Assessment
The subject will be asked to place a vertical stroke on a 100 mm VAS on which the 
left-hand boundary represents no itch, and the right-hand boundary represents itch as
severe as can be imagined.  The distance from the mark to the left-hand boundary will 
be recorded.  See Appendix D.

Skin Discomfort/Pain Visual Analog Scale (VAS) Assessment
The subject will be asked to place a vertical stroke on a 100 mm VAS on which the 
left-hand boundary represents no skin discomfort/pain, and the right-hand boundary 
represents skin discomfort/pain as severe as can be imagined.  The distance from the 
mark to the left-hand boundary will be recorded. See Appendix D.

Subject Global Assessment of Psoriasis Disease Activity (VAS)
The subject will be asked to place a vertical stroke on a 100 mm VAS on which the 
left-hand boundary represents very well, and the right-hand boundary represents very 
poor.  The distance from the mark to the left-hand boundary will be recorded. See 
Appendix D.

Subject’s Assessment of Joint Pain (VAS)
If the subject has a history of Psoriatic Arthritis and it is active at Baseline, the subject 
will be asked to place a vertical stroke on a 100 mm VAS on which the left- hand 
boundary represents very well, and the right-hand boundary represents very poor.  
The distance from the mark to the left-hand boundary will be recorded. See 
Appendix D.

Subject’s Global Assessment of Psoriatic Arthritis Disease Activity (VAS)
If the subject has a history of Psoriatic Arthritis and it is active at Baseline, then the 
subject will be asked to place a vertical stroke on a 100 mm VAS on which the left- 
hand boundary represents no pain, and the right-hand boundary represents pain as 
severe as can be imagined.  The distance from the mark to the left-hand boundary will 
be recorded.  See Appendix D.
Health-Related Quality of Life Assessments
Questionnaires should be administered to the subject in the order that they are described below 
and as indicated in Table of Events Table 1:

Dermatology Life Quality Index (DLQI)
DLQI [54] will be assessed by the subject upon arrival at the site before any other 
procedures or assessments are performed.  The DLQI was developed as a simple, 
compact, and practical questionnaire for use in a dermatology clinical setting to assess 
limitations related to the impact of skin disease [54].  The instrument contains 10 items 
dealing with the subject’s skin.  With the exception of Item Number 7, the subject 
responds on a four-point scale, ranging from “Very Much” to “Not at All.”  Item 
Number 7 is a multi-part item, the first part of which ascertains whether the subject’s 
skin prevented them from working or studying (Yes or No), and if “No,” then the 


19
subject is asked how much of a problem the skin has been at work or study over the past 
week, with response alternatives being “A lot,” “A little,” or “Not at all.”
The DLQI Total score has a possible range from 0 to 30, with 30 corresponding to the 
worst quality of life, and 0 corresponding to the best score.  The developers suggest that 
the DLQI can be grouped into six subscales: symptoms and feelings; daily activities; 
leisure; work/school; personal relationships; and treatment.  Scores for four of the 
subscales (symptoms and feelings, daily activities, leisure, and personal relationships) 
range from 0 to 6; scores for two of the subscales (work/school and treatment) range 
from 0 to 3.  Higher scores correspond to poorer quality of life.  See Appendix E.

The Work Productivity and Activity Impairment Questionnaire: Psoriasis
(WPAI: PSO)
The WPAI: PSO questionnaire is a validated, 6-item self-administered instrument 
used to assess the impact of disease on work productivity in psoriasis due to general 
health or a specified health problem ([55]; Appendix F).
Stress Response Assessment (Only required if subject participates in the optional 
Monitoring of Epidermal Activity)

Numerical N-Back Test
The Numerical N-back test will be performed while the subject is wearing the 
Empatica device to assess stress response. The test will be performed by asking the 
subject to count backwards from one thousand by sevens. The test will terminate at 5 
minutes time or at the point in which the subject completes the task, whichever comes 
sooner. This test will be performed at baseline, visit 2B (+/-5 days), and visit 6.


20
6.
STUDY POPULATION
6.1.
Number of Subjects and Sites
Approximately 55 subjects will be enrolled at UHCMC, University Hospitals Dermatology 
Fairlawn, or Wright State University Boonshoft School of Medicine.  UHCMC 
investigational pharmacy will coordinate investigational product (IP) shipment to WSUSOM 
investigational pharmacy. Goal is to have 25 psoriasis patients aged 18-65 years old and 10 
healthy controls complete the trial (35 total). Total enrollment of 55 is to account for screen 
fails and early terminations.
6.2.
Inclusion Criteria
Subjects must satisfy the following criteria to be enrolled in the study:
1.   Males or females, ≥ 18 and < 65 years of age at the time of signing the 
informed consent document.
2.   Understand and voluntarily sign an informed consent document prior to any study related 
assessments/procedures being conducted.
3.   Able to adhere to the study visit schedule and other protocol requirements.
4. Patients must exhibit AM-endotype psoriasis patients, identified by elevated (>150% of 
normal) levels of any one of the following criteria:

Intermediate (CD14++CD16+) monocytes, OR

Circulating monocyte doublets, OR 

Circulating monocyte-platelet aggregates (MPA).
5.   Diagnosis of chronic plaque psoriasis for at least 12 months prior to Screening.
6.   Have moderate to severe plaque psoriasis at Screening and Baseline as defined by 
a.       BSA ≥5%
b.       sPGA ≥3 (moderate to severe)
7.   Must be a candidate for phototherapy and systemic (including Otezla) therapy.
8.   Must be in good health (except for psoriasis) as judged by the Investigator, based on 
medical history and physical examination.
9. Subject must have completed 5-7 days of successful Empatica device data collection.
(Optional: Only if subject choses to participate)
10. Subject must have consistent internet access and the ability to successfully download the 
Empatica data manager user interface. 
(Optional: Only if subject choses to participate)


21
11.  Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and 
Baseline.  While on investigational product and for at least 28 days after taking the last dose of 
investigational product, FCBP who engage in activity in which conception is possible must use one 
of the approved contraceptive options described below: 
Option 1:  Any one of the following highly effective methods:  hormonal contraception (oral, 
injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; 
or partner’s vasectomy;
OR
Option 2:  Male or female condom (latex condom or non-latex condom NOT made out of 
natural [animal] membrane [for example, polyurethane]; PLUS one additional barrier 
method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive 
sponge with spermicide.
The female subject’s chosen form of contraception must be effective by the time the female subject 
is randomized into the study (for example, hormonal contraception should be initiated at least 28 
days before randomization
Male subjects (including those who have had a vasectomy) who engage in activity in which 
conception is possible must use barrier contraception (male latex condom or non-latex condom NOT 
made out of natural [animal] membrane [for example, polyurethane]) while on investigational 
product and for at least 28 days after the last dose of investigational product.
6.3.
Exclusion Criteria
The presence of any of the following will exclude a subject from enrollment:
1.  Other than psoriasis, history of any clinically significant (as determined by the Investigator) 
cardiac (clinically advanced cardiovascular disease including; Stent, past history of MI, 
thrombotic event or arterial calcification), endocrine, pulmonary, neurologic, psychiatric, 
hepatic, renal, hematologic, immunologic disease, or other major uncontrolled disease.
2.   Any condition, including the presence of laboratory abnormalities, which would place the 
subject at unacceptable risk if he/she were to participate in the study.
3.   Any condition, including other inflammatory diseases or dermatologic conditions that 
confound the ability to interpret data from the study.
4.   Prior history of suicide attempt at any time in the subject’s life time prior to screening or 
randomization, or major psychiatric illness requiring hospitalization within the last 3 
years.
5.   Pregnant or breast feeding.
6.   Have failed more than 3 systemic agents for treatment of psoriasis.
7.   History of allergy to any component of apremilast.
 
8. Had a serious infection (including, but not limited to, hepatitis, pneumonia, sepsis, 
cellulitis, meningitis or pyelonephritis) or have been hospitalized for an infection. 
Subject must be cured of infection > 4 weeks before Screening.


22
9. Have a history of, or ongoing, chronic or recurrent infectious disease, including, but not 
limited to, chronic renal infection, chronic chest infection (e.g., bronchiectasis), sinusitis, 
recurrent urinary tract infection (e.g., recurrent pyelonephritis, chronic nonremitting 
cystitis), an open, draining, or infected skin wound or ulcer.
10. Had a Bacillus Calmette-Guérin (BCG) vaccination within 1 year prior to screening.
11. History of positive human immunodeficiency virus (HIV), or have congenital or acquired 
immunodeficiency (e.g., common variable immunodeficiency disease).
12. Active substance abuse or a history of substance abuse within 6 months prior to
Screening.
13. Bacterial infections requiring treatment with oral or injectable antibiotics, or significant 
viral or fungal infections, within 4 weeks of Screening.  Any treatment and cure for such 
infections must have been completed at least 4 weeks prior to Screening.
14. Malignancy or history of malignancy, except for:
a.   treated [i.e., cured] basal cell or squamous cell in situ skin carcinomas;
b.   treated [i.e., cured] cervical intraepithelial neoplasia [CIN] or carcinoma in situ of 
the cervix with no evidence of recurrence within the previous 5 years.
15. Topical therapy within 2 weeks of study entry (including, but not limited to, topical 
corticosteroids, retinoids or vitamin D analog preparations, tacrolimus, pimecrolimus, or 
anthralin/dithranol).  Exceptions: low-potency corticosteroids will be allowed as 
background therapy and restricted to treatment of the face, axillae, and groin in accordance 
with the manufacturers’ suggested usage during the course of the study (this restricted 
usage should be documented).  Subjects with scalp psoriasis will be permitted to use coal 
tar shampoo and/or salicylic acid scalp preparations on scalp lesions. An unmedicated 
skin moisturizer (e.g. Eucerin®) will be also permitted for body lesions only. Subjects 
should not use these topical treatments within 24 hours prior to the clinic visit.
16. Systemic therapy for psoriasis within 4 weeks prior to study entry (including, but not limited 
to, cyclosporine, corticosteroids, methotrexate, retinoids, mycophenolate, thioguanine, 
hydroxyurea, sirolimus, sulfasalazine, azathioprine, and fumaric acid esters).
17. Use of phototherapy within 4 weeks prior to study entry.
18. Use of any investigational drug within 4 weeks prior to study entry, or 5 
  pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).
19. Prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources.
20. Prior treatment with Apremilast
21. Inability to wash out from biologics (e.g., TNF inhibitors IL-17 inhibitors, IL-12/23 
inhibitors, for 8 weeks). 


23
7.
DESCRIPTION OF STUDY TREATMENTS
7.1.
Description of Investigational Product(s)
7.1.1.
Description of Apremilast
The chemical name of apremilast (CC-10004, Otezla) is acetamide, N-[2-[(1S)-1-(3-
ethoxy-4- 
methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-
isoindol-4-yl].
Apremilast will be provided as 10, 20, or 30 mg tablets in blister cards for titration purposes (see
Appendix N).  Apremilast will be provided as 30 mg tablets in HDPE bottles (approximately 
60tablets) with child-resistant caps for routine dosing.
7.1.2
Treatment Administration and Schedule
Apremilast
Investigational product tablets will be taken orally twice daily, approximately 12 hours apart, 
without restriction of food or drink.  To attempt to mitigate potential mild to moderate headache 
and gastrointestinal (GI) adverse events (primarily nausea), dose titration will be implemented in 
this study at specific times.  
Dosing
During Week 0 (Days 1-7), subjects will be dispensed blister cards with standardized dosing of 
apremilast tablets.  
7.1.3.
Packaging and Labeling
Tablets
The label(s) for apremilast will include drug name, dosage form and strength (where applicable), 
amount of apremilast per container, lot number, expiry date (where applicable), dosing instructions, 
storage conditions.  All apremilast will be supplied by Amgen in HDPE bottles with child-resistant 
caps.  
7.1.4.
Product Accountability and Disposal
The Investigator, or designee, is responsible for taking an inventory of each shipment of Otezla
received, and comparing it with the accompanying Otezla shipping order/packing list.
The Investigator, or designee, will verify the accuracy of the information on the form, sign and 
date it, retain a copy in the study file, and return a copy to Amgen. 
Investigational product will be stored per the storage conditions identified on drug label. At the 
study site, all Otezla will be stored in a locked, safe area to prevent unauthorized access.
Amgen will instruct the Investigator on the return, disposal and/or destruction Otezla if applicable. 
7.1.5.
Investigational Product Compliance


24
Study personnel will review the instructions printed on the package with the study subjects prior 
to dispensing Otezla. The subjects will be instructed to return the Otezla containers, including any 
unused medication, to the study site at each visit for tablet counts and reconciliation.  Subjects 
will be asked whether they have taken their Otezla as instructed at each study visit and will be 
required to complete a medication log at home that will be returned at study visits 3-6.  Any 
problems with compliance will be reviewed with the subject.  
7.1.6.
Rescue Therapy
The initiation of non-study drug therapy to treat worsening of psoriasis, or flare of previously 
inactive skin disease, is strongly discouraged throughout the treatment period. However, should 
rescue therapy be required for the safety and well-being of the subject, such use will be permitted. 
The subject may remain on study drug, unless the rescue therapy is any therapy that may jeopardize 
the subject’s safety if study drug is continued, in the investigator’s and/or Sponsor’s 
opinion.Because the study is not a randomized trial, any subjects that are required to be placed on 
rescue therapy, but continue in the study will have any data after rescue treated as missing values.  
Missing values will be imputed from the average of all subjects completed for those data points. 
Alternatively if rescue therapy is required for > 50% of the patients, then these individuals would 
be analyzed as a separate cohort of patients and will not be analyzed in the grouped data.


25
8.
CONCOMITANT MEDICATIONS AND PROCEDURES
8.1.
Permitted Concomitant Medications and Procedures
Subjects may take any medication that is not restricted by the protocol and would not be 
expected to interfere with the conduct of the study or affect assessments.  Chronic medication 
should be dosed on a stable regimen.
All medications (prescription and non-prescription), treatments and therapies taken by the
subject from screening throughout their entire participation in the study, including those initiated 
prior to the start of the study, must be recorded on the subject’s source document and on the 
appropriate page of the eCRF.  The dose, unit, frequency, route, indication, the date the medication 
was started and the date the medication was stopped (if not ongoing) must be recorded. The 
recording of any permitted topical medications taken for psoriasis should also include the area of 
the body to which they are applied.
The following topical therapies will be permitted:

Low-potency or weak corticosteroids (e.g., Class 6 or 7 in US, such as hydrocortisone, 
desonide, alclometasone dipropionate) will be allowed as background therapy and 
restricted to treatment of the face, axillae, and groin in accordance with the 
manufacturers’ suggested usage during the course of the study (this restricted usage 
should be documented).

Subjects with scalp psoriasis will be permitted to use coal tar shampoo and/or 
salicylic acid scalp preparations on scalp lesions.

An unmedicated skin moisturizer (e.g. Eucerin) will be also permitted for body lesions 
only.
8.2.
Prohibited Concomitant Medications and Procedures
The following psoriasis medications cannot be administered for the duration of the study.

Topical therapy

Topical therapy, unless otherwise specified (including, but not limited to, topical 
corticosteroids, retinoids or vitamin D analog preparations, tacrolimus, 
pimecrolimus, or anthralin/dithranol; or as specified as in Section 8.1).

Systemic Therapy

Systemic therapy including but not limited to cyclosporine, corticosteroids, 
methotrexate, retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, 
sulfasalazine, azathioprine, fumaric acid esters.


26

Phototherapy

UVB or PUVA unless otherwise specified as in Section 8.1

Biologic agents, including:

Adalimumab, etanercept, infliximab, or certolizumab pegol

Ustekinumab
-
IL-17-inhibitors, brodalumab, ixekizumab and secukinumab

Use of any investigational drug or device
8.3.

Prolonged sun exposure or use of tanning booths or other ultraviolet light sources
Required Concomitant Medications and Procedures
Not applicable.


27
9.
STATISTICAL ANALYSES
9.1.
Overview
The objective of the statistical analysis will be to evaluate change in aberrant inflammatory profiles 
of activated blood monocytes (aberrant-monocyte endotype patients (AM-endotype).  Subjects with 
moderate to severe plaque psoriasis will be treated with oral apremilast (Otezla) with standard 
dosing for 16 weeks.  For each subject, we will identify a target biomarker of abnormally elevated 
monocytes, among intermediate, doublets, and platelet doubles.  Each subject will thus have one 
identified monocyte biomarker for which relative percent change will be its basis for analysis in the 
primary outcome. If more than one category is abnormally elevated, then among abnormally 
elevated monocyte biomarkers we will first select doublets if elevated.  If not, then we will select 
intermediate monocytes. For each of the selected abnormally elevated monocyte biomarkers, our 
focus will be on relative percent reduction.  We will specifically assess change from baseline to 16 
weeks by computing relative percent reduction for each subject being treated.  Note for example 
that a change of 1.5% to 1.2% is (1 – (1.2/1.5))*100% = 20% reduction. The median and other 
summary statistics of these percent change values will be computed.  Wilcoxon’s signed rank test 
will be used to evaluate the null hypothesis of the median percent change being 0.  In other words, 
we will test whether or not there has been a reduction in abnormally elevated monocytes.
Secondarily, in an exploratory manner, we will longitudinally model these percent change values 
across time points (baseline, 4, 8, 12, and 16 weeks), to assess trajectory of percent change values.  
We will test for time effects, and consider post-hoc pairwise analyses of time points.  Time will be 
considered as both a continuous covariate with slope parameter, as well as a categorical variable, 
which does not require linearity assumptions.
In analyses treating time as a continuous variable, actual measurements of time (as compared to fixed 
time points by week) will be used in the analyses.
Other outcomes such as PASI will be analyzed similarly.   Note that we will also correlate change 
in our abnormally elevated monocyte markers at various time points with change in PASI, to explore 
possible mechanistic associations.  For a two-sided Wilcoxon test with Type I error of 0.05, power 
is 0.80 if the effect size is 0.60 or greater (assuming an underlying normal distribution).  For 20% 
median reduction, as long as standard deviation of percent change is not larger than 33%, we will 
have effect size of at least 0.60.  These are plausible assumptions given our prior work on treatment 
related monocyte reductions [40].
Because the study is not a randomized trial, any subjects that are required to be placed on rescue 
therapy, but continue in the study will have any data after rescue treated as missing values and 
these missing values will be imputed from the average of all subjects completed. Alternatively if 
rescue therapy is required for > 50% of the patients, then these individuals would be analyzed as a 
separate cohort of patients and will not be analyzed in the grouped data.
9.2.
Background and Demographic Characteristics
Subjects’ age, weight, height and other continuous demographics and baseline characteristics will 
be summarized using descriptive statistics (n, mean, median, standard deviation, minimum, and 
maximum), while gender, race, and other categorical variables will be summarized with 
frequency tabulations.  Medical history data will be summarized using frequency tabulations.


28
9.3.
Subject Disposition
Subject disposition (analysis population allocation, entered, completed, discontinued, along with 
primary reason for discontinuation) will be summarized using frequency and percent by phase.
A summary of subjects randomized by site will be provided.  Protocol violations/deviations will 
be summarized using frequency tabulations. 
10.
ADVERSE EVENTS
10.1.
Monitoring, Recording and Reporting of Adverse Events
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may 
appear or worsen in a subject during the course of a study.  It may be a new intercurrent illness, a 
worsening concomitant illness, an injury, or any concomitant impairment of the subject’s health, 
including laboratory test values (as specified by the criteria below), regardless of etiology.  Any 
worsening (i.e., any clinically significant adverse change in the frequency or intensity of a pre- 
existing condition) should be considered an AE.  A diagnosis or syndrome should be recorded on 
the AE page of the eCRF rather than the individual signs or symptoms of the diagnosis or 
syndrome.
An overdose, accidental or intentional, whether or not it is associated with an AE, or abuse, 
withdrawal, sensitivity or toxicity to an investigational product should be reported as an AE.  If 
an overdose is associated with an AE, the overdose and adverse event should be reported as 
separate terms.
If the sequela of an overdose is an SAE, then the sequela must be reported on an SAE report form. 
The overdose resulting in the SAE should be identified as the cause of the event on the SAE report 
form but should not be reported as an SAE itself.
All subjects will be monitored for AEs during the study.  Assessments may include monitoring 
of any or all of the following parameters:  the subject’s clinical symptoms, laboratory, 
pathological, radiological or surgical findings, physical examination findings, or other 
appropriate tests and procedures.
All AEs will be recorded by the Investigator from the time the subject signs informed consent to
28 days after the last dose of Otezla.AEs and serious adverse events (SAEs) will be recorded on 
the AE page of the eCRF and in the subject’s source documents.  All SAEs must be reported to 
Amgen Drug Safety within 24 hours of the Investigator’s knowledge of the event by facsimile, 
or other appropriate method, using the SAE Report Form, or approved equivalent form.
Psoriasis flare and psoriasis rebound, will be captured as adverse events. General worsening of 
psoriasis should be considered a lack of therapeutic effect and will not be captured as an adverse 
event.
10.2.
Evaluation of Adverse Events
A qualified Investigator will evaluate all adverse events as to:


29
10.2.1.
Seriousness
A serious adverse event (SAE) is any AE occurring at any dose that:

Results in death;

Is life-threatening (i.e. in the opinion of the Investigator, the subject is at immediate 
risk of death from the AE);

Requires inpatient hospitalization or prolongation of existing hospitalization
(hospitalization is defined as an inpatient admission, regardless of length of stay);

Results in persistent or significant disability/incapacity (a substantial disruption of the 
subject’s ability to conduct normal life functions);

Is a congenital anomaly/birth defect;

Constitutes an important medical event.
Important medical events are defined as those occurrences that may not be immediately life 
threatening or result in death, hospitalization, or disability, but may jeopardize the subject or 
require medical or surgical intervention to prevent one of the other outcomes listed above. 
Medical and scientific judgment should be exercised in deciding whether such an AE should be 
considered serious.
Events not considered to be SAEs are hospitalizations for:

A standard procedure for protocol therapy administration.  However, hospitalization 
or prolonged hospitalization for a complication of therapy administration will be 
reported as an SAE.

Routine treatment or monitoring of the studied indication not associated with any 
deterioration in condition.

The administration of blood or platelet transfusion as routine treatment of studied 
indication. However, hospitalization or prolonged hospitalization for a complication 
of such transfusion remains a reportable SAE.

A procedure for protocol/disease-related investigations (e.g., surgery, scans, 
endoscopy, sampling for laboratory tests, bone marrow sampling).  However, 
hospitalization or prolonged hospitalization for a complication of such procedures 
remains a reportable SAE.

Hospitalization or prolongation of hospitalization for technical, practical, or social 
reasons, in absence of an AE.

A procedure that is planned (i.e., planned prior to starting of treatment on study); 
must be documented in the source document and the eCRF.  Hospitalization or 
prolonged hospitalization for a complication remains a reportable SAE.

An elective treatment of a pre-existing condition unrelated to the studied indication.

Emergency outpatient treatment or observation that does not result in admission, 
unless fulfilling other seriousness criteria above.
If an AE is considered serious, both the AE page/screen of the eCRF and the SAE Report Form 
must be completed.
For each SAE, the Investigator will provide information on severity, start and stop dates, 


30
relationship to IP, action taken regarding IP, and outcome.
10.2.2.
Severity / Intensity
For both AEs and SAEs, the Investigator must assess the severity / intensity of the event.
Mild

Asymptomatic or mild symptoms; clinical or diagnostic observations only

Intervention not indicated

Activities of daily living (ADLs) minimally or not affected

No or minimal intervention/therapy may be required
Moderate

Symptom(s) cause moderate discomfort

Local or noninvasive intervention indicated

More than minimal interference with ADLs, but able to carry out daily social and 
functional activities

Drug therapy may be required
Severe (could be non-serious or serious)

Symptoms causing severe discomfort/pain

Symptoms requiring medical/surgical attention/intervention

Interference with ADLs, including inability to perform daily social and functional 
activities (e.g., absenteeism and/or bed rest)

Drug therapy is required
The term “severe” is often used to describe the intensity of a specific event (as in mild, moderate 
or severe myocardial infarction); the event itself, however, may be of relatively minor medical 
significance (such as severe headache).  This criterion is not the same as “serious” which is 
based on subject/event outcome or action criteria associated with events that pose a threat to a 
subject’s life or functioning.
Seriousness, not severity, serves as a guide for defining regulatory obligations.
10.2.3.
Causality
The Investigator must determine the relationship between the administration of IP and the 
occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not suspected:
The temporal relationship of the adverse event to IP 
administration makes a causal relationship unlikely or 
remote, or other medications, therapeutic interventions, or 
underlying conditions provide a sufficient explanation for the 
observed event.
Suspected:
The temporal relationship of the adverse event to IP 
administration makes a causal relationship possible, and other 


31
medications, therapeutic interventions, or underlying conditions 
do not provide a sufficient explanation for the observed event.
If an event is assessed as suspected of being related to a comparator, ancillary or additional IP 
that has not been manufactured or provided by Amgen, please provide the name of the 
manufacturer when reporting the event.
10.2.4.
Duration
For both AEs and SAEs, the Investigator will provide a record of the start and stop dates of the 
event.
10.2.5.
Action Taken
The Investigator will report the action taken with Otezla as a result of an AE or SAE, as 
applicable (e.g., discontinuation of IP, as appropriate) and report if concomitant and/or 
additional treatments were given for the event. 
10.2.6.
Outcome
All SAEs that have not resolved upon discontinuation of the subject’s participation in the study 
must be followed until recovered, recovered with sequelae, not recovered (death due to another 
cause), or death (due to the SAE).
10.3.
Abnormal Laboratory Values
An abnormal laboratory value is considered to be an AE if the abnormality:

results in discontinuation from the study;

requires treatment, modification/ interruption of Otezla dose; or

is judged to be of significant clinical importance.
Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion 
need to be documented as a serious adverse event.
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page/screen of the eCRF.  If the abnormality was not
a part of a diagnosis or syndrome, then the laboratory abnormality should be recorded as the AE.
10.4.
Reporting of Serious Adverse Events
Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in 
addition to being recorded on the AE page/screen of the eCRF.  All SAEs must be reported to 
Amgen Drug Safety within 24 hours of the Investigator’s knowledge of the event by facsimile, 
or other appropriate method, using the SAE Report Form, or approved equivalent form.  This 
instruction pertains to initial SAE reports as well as any follow-up reports.
The Investigator is required to ensure that the data on these forms is accurate and consistent.
This requirement applies to all SAEs (regardless of relationship to IP) that occur during the study 
(from the time the subject signs informed consent to at least 30 days after the last dose of Otezla), 
and those made known to the Investigator at any time thereafter that are suspected of being related 
to Otezla.  SAEs occurring prior to treatment will be captured.
The SAE report should provide a detailed description of the SAE and include summaries of 


32
hospital records and other relevant documents.  If a subject died and an autopsy has been 
performed, copies of the autopsy report and death certificate are to be sent to Amgen Drug Safety 
as soon as these become available. Any follow-up data will be detailed in a subsequent SAE 
Report Form, or approved equivalent form, and sent to Amgen Drug Safety.
Where required by local legislation, the Investigator is responsible for informing the IRB/EC of 
the SAE and providing them with all relevant initial and follow-up information about the event. 
The Investigator must keep copies of all SAE information on file including correspondence with 
Amgen and the IRB/EC.
10.4.1.
Safety Queries
Queries pertaining to SAEs will be communicated from Amgen Drug Safety to the site via 
facsimile or electronic mail.  The response time is expected to be no more than five (5) business 
days.  Urgent queries (e.g., missing causality assessment) may be handled by phone.
10.5.
Expedited Reporting of Adverse Events
For the purpose of regulatory reporting, Amgen Drug Safety will determine the expectedness of 
events suspected of being related to Apremilast based on the Investigator’s Brochure.  
Amgen shall notify the Investigator of the following information:

Any AE associated with the use of Otezla in this study or in other studies that is 
both serious and unexpected (i.e., SUSAR);

Any finding from tests in laboratory animals that suggests a significant risk for human 
subjects including reports of mutagenicity, teratogenicity, or carcinogenicity.
Where required by local legislation, the Investigator shall notify his/her IRB/EC promptly of 
these new serious and unexpected AE(s) or significant risks to subjects.
The Investigator must keep copies of all pertinent safety information on file including 
correspondence with Amgen and the IRB/EC, (see Section 14.2 for record retention 
information).
Amgen Drug Safety Contact Information:
Amgen should receive copies of all safety reports submitted to the FDA, or any other regulatory 
agency, IRB or IEC, within 24 hours of such submission. Such notifications should be submitted 
as E2B, MedWatch or CIOMS I reports using the ISS Safety Fax Transmittal Cover Sheet and 
faxed to 888-814-8653. Cover sheet can be found here:
S:\Derm_Clinical_Trials\Clinical Trials (Investigator Initiated)\07-17-33 Korman - Celgene 
Apremilast
Amgen Drug Safety Contact Information:
Amgen Global Safety
Toll-free #:1-888-814-8653
For countries where the U.S. toll-free # cannot be used: +44-20-7136-1046
Email (Only for sponsors with a secure email connection with Amgen): 
svc-ags-in-us@amgen.com
For Interventional studies with Amgen IMPa:


33
Safety Data
Timeframe for submission to 
Amgen
Send to
Suspected Unexpected 
Serious Adverse Reaction 
(SUSARs)
At time of regulatory submission
Amgen Safety
Pregnancy/Lactation 
exposure and any 
associated 
reports/outcomes (i.e. 
unexpected pregnancy, 
pregnancy of partner, 
spontaneous abortion, 
congenital anomaly etc.)
Within 1 business day of Sponsor 
awareness, for reports meeting serious 
criteria
Not to exceed 15 calendar days of 
Sponsor awareness, for non-serious 
reports
Amgen Safety
a Specific requirements are to be outlined in the Research Agreement.
Please refer to the Serious Adverse Event Report Form / Completion Guidelines or to the 
Pregnancy Report Form / Completion Guidelines.
Pregnancies/lactation and suspected pregnancies (including a positive pregnancy test regardless of 
age or disease state) of a female subject or the female partner of a male subject occurring while the 
subject is on study drug, or within 30 days of the subject’s last dose of study drug, are considered 
immediately reportable events.  Study drug is to be discontinued immediately and the subject 
instructed to return any unused portion of the study drug to the investigator(s).  The pregnancy, 
lactation, suspected pregnancy, or positive pregnancy test must be reported to Amgen Safety 
immediately facsimile using the Pregnancy Report form provided by Amgen.
The female should be referred to an obstetrician-gynecologist experienced in reproductive toxicity 
for further evaluation and counseling.
The Investigator(s) will follow the female subject until completion of the pregnancy, and must notify 
Amgen Safety of the outcome of the pregnancy as a follow-up on the follow up Pregnancy Reporting 
form.
If the outcome of the pregnancy meets the criteria for immediate classification as a SAE (i.e., 
spontaneous or therapeutic abortion [any congenital anomaly detected in an aborted fetus is to be 
documented], stillbirth, neonatal death, or congenital anomaly [including that in an aborted fetus]), 
the Investigator(s) should follow the procedures for reporting SAEs (i.e., report the event to Amgen 
Safety by facsimile within 24 hours of the Investigator’s knowledge of the event).
In the case of a live “normal” birth, Amgen Safety should be advised by facsimile within 24 hours 
of the Investigator’s knowledge of the event.
All neonatal deaths that occur within 30 days of birth should be reported, without regard to causality, 
as SAEs.  In addition, any infant death after 30 days that the Investigator(s) suspects is related to the 
in utero exposure to the study drug should also be reported to Amgen Safety by facsimile within 24 
hours of the Investigators’ knowledge of the event.
If the female is found not to be pregnant, any determination regarding the subject’s continued 
participation in the study will be determined by the Investigator.
Male Subjects
If a female partner of a male subject taking IP becomes pregnant, the male subject taking IP should 


34
notify the Investigator, and the pregnant female partner should be advised to call their healthcare 
provider immediately.
10.6 Analysis of AEs
A listing of AEs in the entire study with their demographic characteristics, adverse event data like start 
date, end date, severity, seriousness, treatment start date, and treatment end date will be recorded. 
Along with this listing, listing of serious adverse events, listing of subjects discontinued from study due to 
adverse events will also be created as a part of an adverse event analysis submission. 
Adverse event (AE) will be reported as summary tables display the number of subjects experiencing an 
AE in each treatment group and will include a standard percentage calculation where the number of 
subjects experiencing an AE are divided by the number of subjects at risk who received a particular 
treatment. Contingency tables will be used to analyze AEs, employing either Chi-square or Fisher’s exact 
test.
Rates of AE occurrence associated with exposure will be expressed as a percentage of the number of 
subjects exposed and experiencing a certain event divided by the total number of subjects exposed, 
regardless of duration of follow-up. 
11.
DISCONTINUATIONS
The following events are considered sufficient reasons for discontinuing a subject from the 
investigational product and/or from the study:

Adverse event(s)

Lack of efficacy

Non-compliance with study drug

Withdrew consent

Study terminated by PI/Sponsor

Lost to follow-up

Death

Protocol violation

Other
The reason for discontinuation should be recorded in the eCRF and in the source documents.


35
12.
EMERGENCY PROCEDURES
12.1.
Emergency Contact
In emergency situations, the Investigator should contact the responsible Clinical Research 
Physician/Medical Monitor or designee by telephone at the number(s) listed on the Emergency 
Contact Information page of the protocol (after title page).
13.
REGULATORY CONSIDERATIONS
13.1.
Good Clinical Practice
The procedures set out in this study protocol pertaining to the conduct, evaluation, and 
documentation of this study are designed to ensure that the Investigator abides by Good Clinical 
Practice (GCP), as described in International Conference on Harmonization (ICH) Guideline E6 
and in accordance with the general ethical principles outlined in the Declaration of Helsinki.  The 
study will receive approval from an IRB/EC prior to commencement.  The Investigator will 
conduct all aspects of this study in accordance with applicable national, state, and local laws of 
the pertinent regulatory authorities.
13.2.
Investigator Responsibilities
Investigator responsibilities are set out in the ICH Guideline for Good Clinical Practice and in the 
local regulations.  
The Investigator should ensure that all persons assisting with the study are adequately informed 
about the protocol, amendments, study treatments, as well as study-related duties and functions. 
The Investigator should maintain a list of Sub-investigators and other appropriately qualified 
persons to whom he or she has delegated significant study-related duties.
The Investigator is responsible for keeping a record of all subjects who sign an informed consent 
document and are screened for entry into the study.  Subjects who fail screening must have the 
reason(s) recorded in the subject’s source documents.
13.3.
Subject Information and Informed Consent
The Investigator must obtain informed consent of a legal representative prior to any study related 
procedures.
Documentation that informed consent occurred prior to the study subject’s entry into the study 
and of the informed consent process should be recorded in the study subject’s source documents 
including the date.  The original informed consent document signed and dated by the study subject 
and by the person consenting the study subject prior to the study subject’s entry into the study, 
must be maintained in the Investigator’s study files and a copy given to the study subject. In 
addition, if a protocol is amended and it impacts on the content of the informed consent, the 
informed consent document must be revised.  Study subjects participating in the study when the 
amended protocol is implemented must be re-consented with the revised version of the informed 
consent document.  The revised informed consent document signed and dated by the study subject 
and by the person consenting the study subject must be maintained in the Investigator’s study files 
and a copy given to the study subject.


36
Remote consenting
Remote consenting will be carried out according to the IRB Guidelines for Remote Electronic 
Consent. The preferred process will utilize audiovisual software (e.g. Zoom) and the Redcap 
e-Consent Framework according to the following guidelines:
1. The potential participant must be in possession of the full IRB-approved informed 
consent document.  This could have been transmitted by email/fax/scan/letter/text.  
2. The study team will arrange a mutually convenient time for a full informed consent 
process with the potential participant. Once the time is arranged ahead, the study 
team member who will be consenting sends a text message “invitation” to the 
potential participant.
3. Once both parties are able to see each other over the virtual visit, the next step 
involves completing identity verification (details must be documented in the study 
team records). The study team member can explain the need to verify identity just as 
if the interaction was in person. The potential participant is asked his/her full name 
and DOB, and is asked to display his/her driver’s license or if not available, any 
state or government-issued picture identification card. 
4. If the bandwidth or connection does not permit a virtual visit with audiovisual 
capabilities, the potential participant can take a picture of their face (also known as a 
“selfie”) and a picture of their photo ID and email* both of these photographs to the 
study team’s University Hospitals e-mail address to verify identity. We strongly 
recommend that any information from the potential participant NOT be sent to the 
personal device or personal email of the study team member, and that a study team 
UH email only be used if this process is needed.
5. Once identity verification is completed, the full informed consent process must 
occur in real-time during the virtual (or audio) visit. 
6. If the potential participant decides to enroll, an electronic signature may be obtained 
during the virtual visit. The study team member must be able to witness the 
signature. Study teams can utilize the process available in REDCap to build this 
electronic capture.
7. If the potential participant is unable to utilize the electronic format for signature, the 
prospective participant can sign a paper copy during the virtual visit, take a picture 
of the signature page, and email that photograph to the study team’s University 
Hospitals e-mail address at the end of the virtual visit.
8. A signature must be received before study procedures begin.
9. If a minor is also assenting during this process, the same steps should be followed, 
but the legal guardian/parent’s attestation can substitute for a picture ID. If the adult 
is the minor’s court-approved legal guardian, a photo of the legal documentation 
must be provided, a picture must be taken, and all information must be emailed to 
the study team’s University Hospitals e-mail address.
Important Note: If you are using a third-party application (e.g., Doxy.me) for a telehealth visit, 
UH recommends saying or otherwise communicating (i.e., in writing via text or e-mail): “Your 
care is being offered through a third-party internet application. By continuing your visit you 
acknowledge that University Hospitals does not control this application or its security and privacy 
policies.” The Office of Research Compliance has provided guidance on WebEx Cloud and 
Doxy.me per the COVID-19 exception telehealth modalities. The platform Doxy.me is 
recommended as it is pre-approved by UH IT.  Other UH approved platforms include MDLIVE 
and Zoom for Healthcare.


37
When using a virtual visit platform (or if using a hospital phone instead due to inadequate 
bandwidth or connection with the potential participant), ready access to:

University Hospitals e-mail account for sharing documents and receipt of any emailed 
pictures (ID, “selfie”, signature); and 

Study team and/or medical records for documentation is required.
13.4.
Confidentiality
Should direct access to medical records require a waiver or authorization separate from the 
subject’s signed informed consent document, it is the responsibility of the Investigator to obtain 
such permission in writing from the appropriate individual.
13.5.
Protocol Amendments
Any amendment to this protocol must be approved by Amgen.  Amendments will be submitted to 
the IRB/EC for written approval. Written approval must be obtained before implementation of the 
amended version occurs.  The written signed approval from the IRB/EC should specifically 
reference the Investigator name, protocol number, study title and amendment number(s) that is 
applicable.  Amendments that are administrative in nature do not require IRB/IEC approval but 
will be submitted to the IRB/IEC for information purposes.
13.6.
Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of the study, the study protocol, informed consent document, and any other 
appropriate documents will be submitted to the IRB/EC with a cover letter or a form listing the 
documents submitted, their dates of issue, and the site (or region or area of jurisdiction, as 
applicable) for which approval is sought.  If applicable, the documents will also be submitted to 
the authorities in accordance with local legal requirements.
Otezla can only be supplied to an Investigator by Amgen after documentation on all ethical and 
legal requirements for starting the study has been received by Amgen.  Before the first subject is 
enrolled in the study, all ethical and legal requirements must be met. 
The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol 
amendments in accordance with local legal requirements.  Amendments must be evaluated to 
determine whether formal approval must be sought and whether the informed consent document 
should also be revised.
The Investigator must keep a record of all communication with the IRB/EC and, if applicable, 
between a Coordinating Investigator and the IRB/EC.  This statement also applies to any 
communication between the Investigator (or Coordinating Investigator, if applicable) and 
regulatory authorities.
13.7.
Ongoing Information for Institutional Review Board / Ethics
Committee
If required by legislation or the IRB/EC, the Investigator must submit to the IRB/EC:

Information on serious or unexpected adverse events as soon as possible;

Periodic reports on the progress of the study;


38

Deviations from the protocol or anything that may involve added risk to subjects.
13.8.
Closure of the Study
Amgen reserves the right to withdraw support from this study at any time for reasonable 
medical or administrative reasons.  Any premature discontinuation will be appropriately 
documented according to local requirements (e.g., IRB/EC, regulatory authorities, etc…).
13.9.
• Annual Reporting:  sponsor’s annual reporting obligations to the 
Regulatory Authorities
For all study types – aggregate reportsa(as applicable):
Safety Data
Timeframe for submission to 
Amgen
Send to
Listing for Safety data 
reconciliationb
Once per year and at the end of the 
study
NASCR 
Manager
Annual Safety Report
(eg, EU Clinical Trial Directive 
DSUR and US IND Annual 
Report)
Annually
NASCR 
Manager
Other aggregate analyses
(any report containing Safety 
data generated during the 
course of the study)
At the time of Sponsor submission to any 
body governing research conduct (eg. 
RA, IRB etc.)
NASCR 
Manager
Final (End of Study Report, 
including):

Unblinding data for blinded 
studies

Reports of unauthorized 
use of a marketed product
At the time of Sponsor submission to any 
body governing research conduct (eg. 
RA, IRB etc.) but no later than 1 calendar 
year of study completion
NASCR 
Manager
a Specific requirements are to be outlined in the Research Agreement.
b Listing for reconciliation should include all ICSRs submitted to Amgen Safety per contract (i.e. for studies in Table 1 
listing should include ADRs, SADRs, Other Safety Findings and serious and non-serious adverse device effects ; for studies 
in Table 2 listing should contain SUSARs, pregnancy and lactation exposure (and any associated reports/outcomes) and 
serious and non-serious adverse device effects; studies in table 3 do not require reconciliation).
14.
DATA HANDLING AND RECORDKEEPING
14.1.
Data/Documents
The Investigator must ensure that the records and documents pertaining to the conduct of the study 
and the distribution of the investigational product are complete, accurate, filed and retained.  
Examples of source documents include: hospital records; clinic and office charts; laboratory 
notes; memoranda; subject’s diaries or evaluation checklists; dispensing records; recorded data 
from automated instruments; copies or transcriptions certified after verification as being accurate 


39
copies; microfiche; x-ray film and reports; and records kept at the pharmacy, and the laboratories, 
as well as copies of eCRFs or CD-ROM.
14.2.
Record Retention
Essential documents must be retained by the Investigator for a minimum of 2 years after the 
formal discontinuation of the study.  The investigator must retain these documents for the time 
period described above or according to local laws or requirements, whichever is longer.  Essential 
documents include, but are not limited to, the following:

Signed informed consent documents for all subjects;

Subject identification code list, screening log (if applicable), and enrollment log;

Record of all communications between the Investigator and the IRB/EC;

Composition of the IRB/EC;

Record of all communications between the Investigator and Amgen;

List of Sub-investigators and other appropriately qualified persons to whom the 
Investigator has delegated significant study-related duties, together with their roles in 
the study, curriculum vitae, and their signatures;

Copies of eCRFs (if paper) and of documentation of corrections for all subjects;

IP accountability records;

Record of any body fluids or tissue samples retained;

All other source documents (subject records, hospital records, laboratory records, 
etc.);

All other documents as listed in Section 8 of the ICH consolidated guideline on GCP 
(Essential Documents for the Conduct of a Clinical Trial).
All study documents should be made available if required by relevant health authorities. 
Investigator/Institution should take measures to prevent accidental or premature destruction of 
these documents.
14.3.
Sharing Data with Participants
If a participant requests information regarding the outcome of our study using their individual 
samples, we will provide a summary of their immune response based on monocyte cell counts 
monitored over the course of the trial. We will provide information based on baseline and final 
visit stating the immune cells either: 1) increased, 2) remained steady, or 3) decreased.  The 
summary will state that research is ongoing and this data will not be used to influence clinical 
care. See email/letter template for sharing this information. This will be emailed to participants or sent 
via standard mail if the patient does not have an email.
15.
QUALITY CONTROL AND QUALITY ASSURANCE


40
All aspects of the study will be carefully monitored by the Investigator/sponsor (Dr. Korman) with 
applicable government regulations with respect to current GCP and standard operating procedures.
15.1.
Study Monitoring and Source Data Verification
The study site ensures that appropriate monitoring procedures are performed before, during and 
after the study


41
16.
REFERENCES
1.
Ackermann, C. and A. Kavanaugh, Economic burden of psoriatic arthritis. Pharmacoeconomics, 
2008. 26(2): p. 121-9.
2.
Feldman, S.R., C. Evans, and M.W. Russell, Systemic treatment for moderate to severe psoriasis: 
estimates of failure rates and direct medical costs in a north-eastern US managed care plan. J 
Dermatolog Treat, 2005. 16(1): p. 37-42.
3.
Fowler, J.F., et al., The impact of psoriasis on health care costs and patient work loss. J Am Acad 
Dermatol, 2008. 59(5): p. 772-80.
4.
Hazard, E., et al., Clinical and economic burden of psoriasis. Manag Care Interface, 2006. 19(4): p. 
20-6.
5.
Kimball, A.B., et al., Economic burden of comorbidities in patients with psoriasis is substantial. J Eur 
Acad Dermatol Venereol, 2011. 25(2): p. 157-63.
6.
Davidovici, B.B., et al., Psoriasis and systemic inflammatory diseases: potential mechanistic links 
between skin disease and co-morbid conditions. J Invest Dermatol, 2011. 130(7): p. 1785-96.
7.
Kim, N., B. Thrash, and A. Menter, Comorbidities in psoriasis patients. Semin Cutan Med Surg, 
2011. 29(1): p. 10-5.
8.
Gelfand, J.M., et al., The risk of lymphoma in patients with psoriasis. J Invest Dermatol, 2006. 
126(10): p. 2194-201.
9.
Mehta, N.N., et al., Patients with severe psoriasis are at increased risk of cardiovascular mortality: 
cohort study using the General Practice Research Database. Eur Heart J, 2010. 31(8): p. 1000-6.
10.
Kimball, A.B., et al., The psychosocial burden of psoriasis. Am J Clin Dermatol, 2005. 6(6): p. 383-92.
11.
Au, L., et al., Suppression of Hyperactive Immune Responses Protects against Nitrogen Mustard 
Injury. J Invest Dermatol, 2015. 135(12): p. 2971-81.
12.
Ziegler-Heitbrock, H.W.L., Heterogeneity of human blood monocytes:  the CD14+ CD16+ 
subpopulation. Immunol.Today, 1996. 17: p. 424-428.
13.
Martinez, F.O., The transcriptome of human monocyte subsets begins to emerge. J Biol, 2009. 
8(11): p. 99.
14.
Ancuta, P., et al., Transcriptional profiling reveals developmental relationship and distinct biological 
functions of CD16+ and CD16- monocyte subsets. BMC Genomics, 2009. 10: p. 403.
15.
Wong, K.L., et al., Gene expression profiling reveals the defining features of the classical, 
intermediate, and nonclassical human monocyte subsets. Blood, 2011. 118(5): p. e16-31.
16.
Zawada, A.M., et al., SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. 
Blood, 2011. 118(12): p. e50-61.
17.
Zawada, A.M., et al., Monocyte heterogeneity in human cardiovascular disease. Immunobiology, 
2012.
18.
Ziegler-Heitbrock, L., et al., Nomenclature of monocytes and dendritic cells in blood. Blood, 2010. 
116(16): p. e74-80.
19.
Geissmann, F., S. Jung, and D.R. Littman, Blood monocytes consist of two principal subsets with 
distinct migratory properties. Immunity, 2003. 19(1): p. 71-82.
20.
Auffray, C., M.H. Sieweke, and F. Geissmann, Blood monocytes: development, heterogeneity, and 
relationship with dendritic cells. Annu Rev Immunol, 2009. 27: p. 669-92.
21.
Shantsila, E., et al., Immunophenotypic characterization of human monocyte subsets: possible 
implications for cardiovascular disease pathophysiology. J Thromb Haemost, 2011. 9(5): p. 1056-
66.
22.
Gallego, C., et al., Toll-like receptors participate in macrophage activation and intracellular control 
of Leishmania (Viannia) panamensis. Infect Immun. 79(7): p. 2871-9.
23.
Cao, L., et al., Psoriasis and cardiovascular risk factors: Increased serum myeloperoxidase and 
corresponding immunocellular overexpression by Cd11b+ CD68+ macrophages in skin lesions. 


42
American Journal of Translational Research, 2013. IN PRESS.
24.
Tapp, L.D., et al., The CD14++CD16+ monocyte subset and monocyte-platelet interactions in 
patients with ST-elevation myocardial infarction. J Thromb Haemost, 2012. 10(7): p. 1231-41.
25.
Tapp, L.D., et al., TLR4 expression on monocyte subsets in myocardial infarction. J Intern Med, 
2012. 273(3): p. 294-305.
26.
Garcia-Rodriguez, S., et al., Increased gene expression of Toll-like receptor 4 on peripheral blood 
mononuclear cells in patients with psoriasis. J Eur Acad Dermatol Venereol, 2011.
27.
Benoit, S., et al., Elevated serum levels of calcium-binding S100 proteins A8 and A9 reflect disease 
activity and abnormal differentiation of keratinocytes in psoriasis. Br J Dermatol, 2006. 155(1): p. 
62-6.
28.
Funderburg, N.T., et al., Shared monocyte subset phenotypes in HIV-1 infection and in uninfected 
subjects with acute coronary syndrome. Blood, 2012. 120(23): p. 4599-608.
29.
Chiu, Y.G., et al., CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic 
arthritis. Arthritis Res Ther, 2010. 12(1): p. R14.
30.
Moniuszko, M., et al., Enhanced frequencies of CD14++CD16+, but not CD14+CD16+, peripheral 
blood monocytes in severe asthmatic patients. Clin Immunol, 2009. 130(3): p. 338-46.
31.
Mysliwska, J., et al., Expansion of CD14+CD16+ monocytes producing TNF-alpha in complication-
free diabetes type 1 juvenile onset patients. Cytokine, 2012. 60(1): p. 309-17.
32.
Hanai, H., et al., Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in 
patients with inflammatory bowel disease. Am J Gastroenterol, 2008. 103(5): p. 1210-6.
33.
Skrzeczynska, J., et al., CD14+CD16+ monocytes in the course of sepsis in neonates and small 
children: monitoring and functional studies. Scand J Immunol, 2002. 55(6): p. 629-38.
34.
Blumenstein, M., et al., Cytokine production precedes the expansion of CD14+CD16+ monocytes in 
human sepsis: a case report of a patient with self-induced septicemia. Shock, 1997. 8(1): p. 73-5.
35.
Fingerle, G., et al., The novel subset of CD14+/CD16+ blood monocytes is expanded in sepsis 
patients. Blood, 1993. 82(10): p. 3170-6.
36.
Schlitt, A., et al., CD14+CD16+ monocytes in coronary artery disease and their relationship to serum 
TNF-alpha levels. Thromb Haemost, 2004. 92(2): p. 419-24.
37.
Rogacev, K.S., et al., CD14++CD16+ Monocytes Independently Predict Cardiovascular Events: A 
Cohort Study of 951 Patients Referred for Elective Coronary Angiography. J Am Coll Cardiol, 2012. 
60(16): p. 1512-20.
38.
Wrigley, B.J., et al., CD14++CD16+ monocytes in patients with acute ischaemic heart failure. Eur J 
Clin Invest, 2013. 43(2): p. 121-30.
39.
Brunner, P.M., et al., Infliximab induces downregulation of the IL-12/IL-23 axis in 6-sulfo-LacNac 
(slan) dendritic cells and macrophages. J Allergy Clin Immunol, 2013.
40.
Golden, J.B., et al., Chronic Psoriatic Skin Inflammation Leads to Increased Monocyte Adhesion and 
Aggregation. J Immunol, 2015. 195(5): p. 2006-18.
41.
Schafer, P.H., et al., Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-
inflammatory activity in vitro and in a model of psoriasis. British Journal of Pharmacology, 2010. 
159(4): p. 842-855.
42.
Singri, P., D.P. West, and K.B. Gordon, Biologic therapy for psoriasis - The new therapeutic frontier. 
Archives of Dermatology, 2002. 138(5): p. 657-663.
43.
Chaudhari, U., et al., Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a 
randomised trial. Lancet, 2001. 357(9271): p. 1842-7.
44.
Lebwohl, M., Psoriasis. Lancet, 2003. 361(9364): p. 1197-204.
45.
Krueger, G.G., et al., A human interleukin-12/23 monoclonal antibody for the treatment of 
psoriasis. N Engl J Med, 2007. 356(6): p. 580-92.
46.
Desai, S.B. and D.E. Furst, Problems encountered during anti-tumour necrosis factor therapy. Best 
Practice & Research in Clinical Rheumatology, 2006. 20(4): p. 757-790.
47.
Keane, J., et al., Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-


43
neutralizing agent. New England Journal of Medicine, 2001. 345(15): p. 1098-1104.
48.
Carey, W., et al., Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am 
Acad Dermatol, 2006. 54(4 Suppl 1): p. S171-81.
49.
Gordon, K., et al., Definitions of measures of effect duration for psoriasis treatments. Arch 
Dermatol, 2005. 141(1): p. 82-4.
50.
Fredriksson, T. and U. Pettersson, Severe psoriasis -- oral therapy with a new retinoid. 
Dermatologica, 1978. 157: p. 238-244.
51.
Fries, J.F., et al., Measurement of Patient Outcome in Arthritis. Arthritis and Rheumatism, 1980. 
23(2): p. 137-145.
52.
Bruce, B. and J.F. Fries, The Stanford Health Assessment Questionnaire: A review of its history, 
issues, progress, and documentation. Journal of Rheumatology, 2003. 30(1): p. 167-178.
53.
Aletaha, D., et al., Responsiveness of the health assessment questionnaire disability index (HAQ) to 
biologics in comparison to placebo in clinical trials of rheumatoid arthritis (RA): Effects of RA 
duration. Annals of the Rheumatic Diseases, 2006. 65: p. 95-95.
54.
Finlay, A.Y. and G.K. Khan, Dermatology Life Quality Index (Dlqi) - a Simple Practical Measure for 
Routine Clinical Use. Clinical and Experimental Dermatology, 1994. 19(3): p. 210-216.
55.
Reilly, M., et al., Preliminary Validation of the Work Productivity Activity Impairment (Wpai) in 
Caregivers of Children Hospitalized for Respiratory Illness (Wpai: Chri) in Germany and Canada. 
Value in Health, 2012. 15(7): p. A650-A650.


44
17.
APPENDICES
Appendix A: Psoriasis Area Severity Index (PASI)
Source:  Frederiksson, 1978.


45
Appendix B:  Physician’s Global Assessments (PGA)
Static Physician’s Global Assessment (sPGA)
Score
Category
Description
0
Clear
Plaque elevation = 0 (no elevation over normal skin)
Scaling = 0 (no evidence of scaling)
Erythema = 0 (except for residual hyperpigmentation/
hypopigmentation)
1
Almost Clear
Plaque elevation = ± (possible but difficult to ascertain whether 
there is a slight elevation above normal skin)
Scaling = ± (surface dryness with some desquamation)
Erythema = ± (faint, diffuse pink or slight red coloration)
2
Mild
Plaque elevation = slight (slight but definite elevation, typically 
edges are indistinct or sloped)
Scaling = fine (fine scale partially or mostly covering lesions)
Erythema = mild (light red coloration)
3
Moderate
Plaque elevation = marked (marked definite elevation with rough 
or sloped edges)
Scaling = coarser (coarser scale covering most or all of the 
lesions)
Erythema = moderate (definite red coloration)
4
Severe
Plaque elevation = marked (marked elevation typically with hard 
or sharp edges)
Scaling = coarser (coarse, non-tenacious scale predominates 
covering most or all of the lesions)
Erythema = severe (very bright red coloration)


Appendix C:  Disability Index of the Health Assessment Questionnaire
46


Appendix C: Disability Index of the Health Assessment Questionnaire
47


Appendix D: Visual Analog Scales (VAS)
48
Subject’s Assessment of Pruritus (Itch)
On average, how much itch have you had because of your condition in the past week?
Subject’s Assessment of Skin Discomfort/Pain
On average, how much skin discomfort/pain have you had because of your condition in 
the past week?
Please use a vertical stroke
No pain at all 
Worst possible pain
0 mm 
100 mm
Please note: VAS above is not drawn to scale and is for illustrative purposes only.


Appendix D: Visual Analog Scales (VAS) (Continued)
49
Subject’s Global Assessment of Psoriasis Disease Activity
Considering all the ways your psoriasis affects you, on average, how have you been 
doing in the past week?
Subject’s Assessment of Joint Pain
On average, how much pain have you had in your joints because of your psoriatic 
arthritis condition in the past week?
Please note: VAS above is not drawn to scale and is for illustrative purposes only.


Appendix D: Visual Analog Scales (VAS) (Continued)
50
Subject’s Global Assessment of Psoriatic Arthritis Disease Activity
Considering all the ways your arthritis affects you, on the average, how have you been doing in the past week?
Please note: VAS above is not drawn to scale and is for illustrative purposes only.
Please use a vertical stroke
Very well
Very Poor
0mm
100 mm


Appendix E: The Dermatology Life Quality Index (DLQI)
51


Appendix F: Work Productivity and Activity Impairment
Questionnaire: Psoriasis (WPAI:PSO)
52
The following questions ask about the effect of your psoriasis on your ability to work and perform regular 
activities. Please fill in the blanks or circle a number, as indicated.
1)
Are you currently employed (working for pay)?
____NO
___YES
If NO, check “NO” and skip to question 6
The next questions are about the past seven days, not including today.
2)
During the past seven days, how many hours did you miss from work because of problems associated 
with your psoriasis? Include hours you missed on sick days, times you went in late, left early, etc. 
because of psoriasis. Do not include time you missed to participate in this study.
______HOURS
3)
During the past seven days, how many hours did you miss from work because of any other reason, 
such as vacation, holidays, time off to participate in this study?
______HOURS
4)
During the past seven days, how many hours did you actually work? 
______HOURS (If “0”, skip to question 6)
5)
During the past seven days, how much did psoriasis affect your productivity while you were working?  
Think about days you were limited in the amount or kind of work you could do, days you accomplished 
less than you would like, or days you could not do your work as carefully as usual.  If psoriasis affected 
your work only a little, choose a low number.  Choose a high number if psoriasis affected your work a 
great deal.
Psoriasis had no
Psoriasis completely
effect on my work
0
1
2
3
4
5
6
7
8
9
10
prevented me from
working
CIRCLE A NUMBER
6)
During the past seven days, how much did psoriasis affect your ability to do your regular daily 
activities, other than work at a job?  By regular activities, we mean the usual activities you do, such as 
work around the house, shopping, child care, exercising, studying, etc. Think about times you were 
limited in the amount or kind of activities you could do and times you accomplished less than you would 
like.  If psoriasis affected your activities only a little, choose a low number.  Choose a high number if 
psoriasis affected your activities a great deal.
Psoriasis had no
Psoriasis completely
effect on my 
daily activities
0
1
2
3
4
5
6
7
8
9
10
prevented me from 
doing my daily activities
CIRCLE A NUMBER
WPAI:PSO (US English)


Appendix G: Blister Card Configuration
53
CC-10004-PSOR-010 30m